OSU Antithrombotic Management of Symptomatic PAD Without Revascularization
Antithrombotic Management in Peripheral Arterial Disease (PAD) post procedure differs from PAD without an intervention.
Provided byAccording to the Anticoagulation Forum Faculty (2026), "Peripheral Arterial Disease (PAD) is an atherosclerotic disease process causing partial or complete obstruction of the lower extremity peripheral arteries, leading to ischemic symptoms and damage ranging from intermittent claudication to pain at rest to tissue loss. Diagnosis can be done with imaging (e.g., CT angiography) or vascular lab (ankle-brachial index/toe-brachial index). Medical management with antithrombotic medications is a mainstay of therapy, found to reduce major adverse cardiac and limb events including amputation and need for revascularization."
This guide supports antithrombotic decisions for adults with symptomatic peripheral artery disease (PAD) who have not had revascularization. Limb symptoms in PAD range from claudication that limits function to chronic limb-threatening ischemia (Bonaca et al., 2020). In the COMPASS trial, rivaroxaban 2.5 mg twice daily added to aspirin (dual pathway inhibition, DPI) reduced major adverse cardiovascular and limb events compared with aspirin alone, with more major bleeding, mostly gastrointestinal. The guide asks about current anticoagulant and antiplatelet therapy, aspirin allergy, kidney function (CrCl below 15 mL/min), medications that interact with rivaroxaban, cost and bleeding risk. It then suggests DPI with rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily, aspirin alone when bleeding risk is high, clopidogrel when aspirin can’t be used, and cilostazol for claudication unless the patient has heart failure or cardiomyopathy.
The decision tree used in this app was developed by the Anticoagulation Forum Faculty,* called the Antithrombotic Clinical Guidance: PAD and Dual Pathway Inhibition Therapy. The following disclaimer is posted by the AC Forum, "Antithrombotic Clinical Guidance are Anticoagulation Forum’s best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients."
*2021 Faculty: Geoffrey Barnes, MD, MSc; Henry Han, MD; Nichole Sherwood, PharmD; Bishoy Ragheb, PharmD; Marc Bonaca, MD, MPH; Eva Kline-Rogers, MS, NP; 2026 Update Faculty: Surabhi Palkimas, PharmD, MBA; Taylor Robichaux, PharmD, BCPS, CACP
All questions & possible results
Part I: DPI Algorithm in Symptomatic PADTitle not visible
Is the patient already on short-term anticoagulation (e.g., VTE initial treatment)?
Select one option:
- No
- Yes (Patient may NOT be a candidate for Dual Pathway Inhibition (DPI) with rivaroxaban PLUS aspirin at this time.)
Is the patient already on long-term anticoagulation for AF, mechanical valve, antiphospholipid syndrome (APS), or extended venous thromboembolism (VTE) treatment?
Select one option:
- No
- Yes (Current use of oral anticoagulants for another condition may be a contraindication for DPI or DAPT in the treatment of PAD)
Is the patient already taking dual antiplatelet therapy for that is required for > 1 month?
*e.g., acute coronary syndrome, recent DES placement inn coronary or below knee arteries
Select one option:
- No
- Yes (Patient may NOT be a candidate for a change to DPI at this time. Further assessment required.)
Part II: DPI Algorithm in Symptomatic PADTitle not visible
Is CrCl < 15 ml/min?
Select one option:
- No
- Yes (CrCl <15 ml/min is a contraindication for Rivaroxaban)
Allergy to aspirin?
Select one option:
- No
- Yes (ASA allergy is a contraindication for DPI or DAPT. Consider clopidogrel monotherapy as an alternative.)
Is the patient already prescribed or using aspirin?
Select one option:
- No
- Yes
At increased risk of bleeding?
Bleeding Risk Factors to Consider:
- Concurrent NSAID or other antiplatelet agents
- History of hemorrhagic stroke, intracranial hemorrhage, or significant bleeding
- Recent GI ulceration
- Active malignant neoplasms at risk of bleeding
- History of vascular aneurysms
- History of coagulopathies/bleeding disorders
- Uncontrolled hypertension (SBP > 160 mmHg)
- Heavy alcohol use or esophageal varices
- Acute liver or renal failure
- Recent trauma or surgery
These factors represent a sampling of bleeding risk factors from validated tools (HAS-BLED, HEMORR2HAGES, IMPROVE-VTE) and the primary literature (VOYAGER-PAD, COMPASS.)
Select one option:
- No
- Yes (Increased bleed risk may be a contraindication for DPI or DAPT)
Is Rivaroxaban cost or lack of insurance a barrier?
Select one option:
- No
- Yes
Is the patient already taking other medication that is contraindicated for use with rivaroxaban?
Contraindication Examples
- Combined CYP3a and P-gp inducers and inhibitors (ketoconazole, ritonavir, erythromycin, carbamazepine, phenytoin, rifampin, St. John’s wort, etc.) - Xarelto Package Insert. Janssen Pharmaceuticals, 2023.
Select one option:
- No
- Yes
Possible results
Symptomatic PAD: Consider DPI. If bleed risk, consider aspirin daily only
Treatment Options
If Symptomatic - Dual Pathway Inhibition (DPI):
- Rivaroxaban 2.5mg BID -PLUS-
- Aspirin 81 mg daily
If Symptomatic & high bleed risk - Monotherapy
- Aspirin 81mg daily
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Footnote
- The rationale behind dual pathway inhibition is to block two different mechanisms for platelet activation to further reduce thrombotic risk. In the COMPASS Trial, the combination of rivaroxaban (a factor Xa inhibitor) and aspirin has been shown to reduce the rates of MACE and MALE (6% vs. 9%, HR 0.69, P < 0.001) versus aspirin monotherapy without increases in fatal or nonfatal bleeding or intracranial hemorrhage.
- Major bleeding was increased in DPI vs. ASA (3% vs. 2%, HR 1.61, p=0.008) and was driven by increased gastrointestinal bleeding, and front-loaded in the first year (COMPASS Trial).
- For more information, view the Anticoagulation Forum Rapid Resource on PAD and DPI.
- Factor Xa inhibitors (rivaroxaban) blocks platelet activation by inhibition of thrombin formation, while aspirin, a COX-1 inhibitor, blocks platelet activation via inhibition of thromboxane A2.
CrCl < 15 ml/min: May NOT be a candidate for Dual Pathway Inhibition (DPI) with Rivaroxaban PLUS aspirin at this time (Symptomatic PAD)
Possible reasons selected that may disqualify DPI as a safe treatment option:
- CrCl < 15ml/min
- Medication cost or lack of insurance coverage: Consider consult with Pharmacy or Social Work for assistance.
- Taking other medication that is contraindicated for use with rivaroxaban
Treatment Options
If Symptomatic - Dual Pathway Inhibition (DPI):
- Rivaroxaban 2.5mg BID -PLUS-
- Aspirin 81 mg daily
If Symptomatic & high bleed risk - Monotherapy
- Aspirin 81mg daily
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Footnote
- The rationale behind dual pathway inhibition is to block two different mechanisms for platelet activation to further reduce thrombotic risk. In the COMPASS Trial, the combination of rivaroxaban (a factor Xa inhibitor) and aspirin has been shown to reduce the rates of MACE and MALE (6% vs. 9%, HR 0.69, P < 0.001) versus aspirin monotherapy without increases in fatal or nonfatal bleeding or intracranial hemorrhage.
- Major bleeding was increased in DPI vs. ASA (3% vs. 2%, HR 1.61, p=0.008) and was driven by increased gastrointestinal bleeding, and front-loaded in the first year (COMPASS Trial).
- For more information, view the Anticoagulation Forum Rapid Resource on PAD and DPI.
- Factor Xa inhibitors (rivaroxaban) blocks platelet activation by inhibition of thrombin formation, while aspirin, a COX-1 inhibitor, blocks platelet activation via inhibition of thromboxane A2.
Symptomatic PAD & Bleed Risk! Consider aspirin daily as monotherapy. May NOT be a candidate for DPI as this time.
Treatment Options
If Symptomatic - Dual Pathway Inhibition (DPI):
- Rivaroxaban 2.5mg BID -PLUS-
- Aspirin 81 mg daily
If Symptomatic & high bleed risk - Monotherapy
- Aspirin 81mg daily
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Footnote
- The rationale behind dual pathway inhibition is to block two different mechanisms for platelet activation to further reduce thrombotic risk. In the COMPASS Trial, the combination of rivaroxaban (a factor Xa inhibitor) and aspirin has been shown to reduce the rates of MACE and MALE (6% vs. 9%, HR 0.69, P < 0.001) versus aspirin monotherapy without increases in fatal or nonfatal bleeding or intracranial hemorrhage.
- Major bleeding was increased in DPI vs. ASA (3% vs. 2%, HR 1.61, p=0.008) and was driven by increased gastrointestinal bleeding, and front-loaded in the first year (COMPASS Trial).
- For more information, view the Anticoagulation Forum Rapid Resource on PAD and DPI.
- Factor Xa inhibitors (rivaroxaban) blocks platelet activation by inhibition of thrombin formation, while aspirin, a COX-1 inhibitor, blocks platelet activation via inhibition of thromboxane A2.
Medication cost or contraindication: May NOT be a candidate for Dual Pathway Inhibition (DPI) with Rivaroxaban PLUS aspirin at this time (Symptomatic PAD)
Possible reasons selected that may disqualify DPI as a safe treatment option:
- CrCl < 15ml/min
- Medication cost or lack of insurance coverage: Consider consult with Pharmacy or Social Work for assistance.
- Taking other medication that is contraindicated for use with rivaroxaban
Treatment Options
If Symptomatic - Dual Pathway Inhibition (DPI):
- Rivaroxaban 2.5mg BID -PLUS-
- Aspirin 81 mg daily
If Symptomatic & high bleed risk - Monotherapy
- Aspirin 81mg daily
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Footnote
- The rationale behind dual pathway inhibition is to block two different mechanisms for platelet activation to further reduce thrombotic risk. In the COMPASS Trial, the combination of rivaroxaban (a factor Xa inhibitor) and aspirin has been shown to reduce the rates of MACE and MALE (6% vs. 9%, HR 0.69, P < 0.001) versus aspirin monotherapy without increases in fatal or nonfatal bleeding or intracranial hemorrhage.
- Major bleeding was increased in DPI vs. ASA (3% vs. 2%, HR 1.61, p=0.008) and was driven by increased gastrointestinal bleeding, and front-loaded in the first year (COMPASS Trial).
- For more information, view the Anticoagulation Forum Rapid Resource on PAD and DPI.
- Factor Xa inhibitors (rivaroxaban) blocks platelet activation by inhibition of thrombin formation, while aspirin, a COX-1 inhibitor, blocks platelet activation via inhibition of thromboxane A2.
Symptomatic PAD Plus Other Indication for Short-term Anticoagulation: Continue current antithrombotic therapy as prescribed. Revisit Dual Pathway Inhibition (DPI) - Reconsider in 1-6 months
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Symptomatic PAD Plus Other Indication for Anticoagulation: Continue Dual Antiplatelet Therapy (DAPT) with P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, etc.) PLUS aspirin. Revisit Dual Pathway Inhibition (DPI) in 3-6 months.
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Symptomatic PAD Plus Other Indication for Long-term Anticoagulation: Continue current antithrombotic therapy as prescribed.
For claudication symptoms consider:
- Cilostazol 75mg BID: Do NOT use in the presence of heart failure or cardiomyopathy.
Literature
2024 Lower Extremity Peripheral Artery Disease Guideline-at-a-Glance. J Am Coll Cardiol. 2024 Jun 18;83(24):2605-2609.
https://pubmed.ncbi.nlm.nih.gov/38752900/2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 11;149(24):e1313-e1410.
https://pubmed.ncbi.nlm.nih.gov/38743805/Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.
https://pubmed.ncbi.nlm.nih.gov/32222135/Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI. 25 April 2020.
https://www.acc.org/membership/sections-and-councils/fellows-in-training-section/section-updates/2020/05/05/10/42/antiplatelet-therapy-for-high-bleeding-risk-patients-undergoing-pciBleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010 Jun 15;121(23):2575-83.
https://pubmed.ncbi.nlm.nih.gov/20516378/2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Mar 21;135(12):e686-e725.
https://pubmed.ncbi.nlm.nih.gov/27840332/Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-4024.
https://pubmed.ncbi.nlm.nih.gov/34279602/
- Creator
Anticoagulation Forum:, Geoffrey Barnes, MD, MSc | Sahil Parikh, MD | Diane Wirth, ANP, CACPRapid Resource
- Provided by
OSU Center for Health Sciences
- Primary Contributor
Kelly Rudd, PharmD, BCPS, CACP, FCCPClinical Associate Professor of Medicine, Oklahoma State University Center for Health SciencesOSU Center for Health Sciences
- Contributor
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation